Overcoming resistance to targeted therapy in cancer

克服癌症靶向治疗的耐药性

• 批准号: 9131668
• 负责人: Levi A. Garraway
• 金额: $ 83.13万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-24 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9131668
• 关键词: Advanced Malignant Neoplasm; Aftercare; Antineoplastic Agents; BRAF gene; Biopsy; Bypass; Categories; Cells; Chromatin; Clinical; Dependency; Disseminated Malignant Neoplasm; Drug Combinations; Drug resistance; Evolution; Glean; Goals; Health; Individual; MAP Kinase Gene; Malignant Neoplasms; Medical; Mitogen-Activated Protein Kinases; Modality; Nature; Oncogenes; Oncogenic; Output; Pathway interactions; Patients; Pharmaceutical Preparations; Refractory; Regimen; Regulation; Research; Resistance; Resistance development; Sampling; Signal Transduction; Testing; Therapeutic; Tissues; Work; anti-cancer therapeutic; base; cancer type; design; insight; kinase inhibitor; melanoma; mutant; neoplastic cell; novel therapeutics; programs; resistance mechanism; targeted treatment; tumor; tumor progression

 DESCRIPTION (provided by applicant): Overcoming resistance to targeted therapy in cancer Project Summary The challenge of drug resistance represents a pervasive barrier that confounds the ultimate goal of cure or long-term control of metastatic cancer. Intensive studies of resistance to targeted therapies by our group in recent years have revealed three over-arching challenges. First, resistance is multifactorial: many individual resistance mechanisms thwart the efficacy of various targeted anticancer therapeutic regimens, and there is no evidence that their discovery has saturated. Second, resistance is heterogeneous: multiple different resistance mechanisms often arise in a given patient-even within a single tumor lesion1. Third, resistance is vastly under-sampled in the clinical arena: few paired pre-treatment and post-resistance biopsies are obtained clinically, and such tissues are only seldom subjected to systematic characterization2. The guiding hypothesis of this research is that the spectrum of resistance mechanisms for any given cancer therapeutic modality might coalesce onto a much smaller set of critical downstream effector "nodes". Discerning the mechanisms operant within such "points of coalescence" should yield new insights into oncogenic dependencies and illuminate guiding principles for the design of novel therapeutic combinations. In recent years, we have evaluated this "coalescence hypothesis" by systematically characterizing mechanisms of resistance to MAP kinase pathway inhibition in BRAF-mutant melanoma and other oncogene- driven cancers. Indeed, many individual MAP kinase resistance mechanisms may coalesce at the level of transcriptional (or chromatin) regulation. This convergence re-engages core MAPK transcriptional program(s) or alternative (ERK-independent) transcriptional programs arising from bypass signaling or germane to "pathway-indifferent" cell states. Accordingly, one objective of this work is to define the convergent downstream outputs elaborated by MAP kinase inhibitor resistance mechanisms, and the factors that govern them. In parallel, we will characterize the coalescence of resistance mechanisms to targeted therapeutics in other cancers. Finally, we will describe drug-resistant and "drug-indifferent" cell states in treatment-refractory tumors. Detailed characterization of resistance categories and the mechanistic coalescence implied therein may reveal fundamental new insights into the nature of cancer dependencies and their evolution during tumor progression and treatment. Insights gleaned from this research may aid the design of higher-order therapeutic combinations that attack multiple tumor dependencies and resistance nodes. This framework for studying the mechanistic coalescence that underpins drug resistance is applicable to many cancer types. Therefore, these efforts could offer guiding principles that become generalizable across many tumor types and therapeutic modalities.